

Highlights of This Issue 3975

SPECIAL FEATURES

CCR Translations

- 3977** Dose-Finding Methods: Moving Away from the 3 + 3 to Include Richer Outcomes
Xavier Paoletti, Damien Drubay, and Laurence Collette
See related article, p. 3994

CCR Perspectives in Regulatory Science and Policy

- 3980** The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
Kenneth C. Anderson, Daniel Auclair, Gary J. Kelloff, Caroline C. Sigman, Hervé Avet-Loiseau, Ann T. Farrell, Nicole J. Gormley, Shaji K. Kumar, Ola Landgren, Nikhil C. Munshi, Michele Cavo, Faith E. Davies, Alessandra Di Bacco, Jennifer S. Dickey, Steven I. Gutman, Howard R. Higley, Mohamad A. Hussein, J. Milburn Jessup, Ilan R. Kirsch, Richard F. Little, Robert D. Loberg, Jens G. Lohr, Lata Mukundan, James L. Omel, Trevor J. Pugh, Gregory H. Reaman, Michael D. Robbins, A. Kate Sasser, Nancy Valente, and Elena Zamagni

Statistics in CCR

- 3994** Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials
Fangrong Yan, Sumithra J. Mandrekar, and Ying Yuan
See related commentary, p. 3977

Molecular Pathways

- 4004** Molecular Pathways: Metabolic Control of Histone Methylation and Gene Expression in Cancer
Thai Q. Tran, Xazmin H. Lowman, and Mei Kong

Review

- 4010** Genome-Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality
Brandon Mapes, Omar El Charif, Shereen Al-Sawwaf, and M. Eileen Dolan

CANCER THERAPY: CLINICAL

- 4020** Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs
Diogo D.G. Bugano, Kenneth Hess, Denis L.F. Jardim, Alona Zer, Funda Meric-Bernstam, Lillian L. Siu, Albiruni R.A. Razak, and David S. Hong
- 4027** Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma
Vivek Subbiah, Christian Meyer, Ralph Zinner, Funda Meric-Bernstam, Marianna L. Zahurak, Ashley O'Connor, Jason Roszik, Kenna Shaw, Joseph A. Ludwig, Razelle Kurzrock, and Nilofer A. Azad
- 4035** A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Bojana Jovanović, Ingrid A. Mayer, Erica L. Mayer, Vandana G. Abramson, Aditya Bardia, Melinda E. Sanders, M. Gabriela Kuba, Monica V. Estrada, J. Scott Beeler, Timothy M. Shaver, Kimberly C. Johnson, Violeta Sanchez, Jennifer M. Rosenbluth, Patrick M. Dillon, Andres Forero-Torres, Jenny C. Chang, Ingrid M. Meszoely, Ana M. Grau, Brian D. Lehmann, Yu Shyr, Quanhu Sheng, Sheau-Chiann Chen, Carlos L. Arteaga, and Jennifer A. Pietenpol
- 4046** A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer
Lee S. Schwartzberg, Denise A. Yardley, Anthony D. Elias, Manish Patel, Patricia LoRusso, Howard A. Burris, Ayca Guzalp, Amy C. Peterson, Martha E. Blaney, Joyce L. Steinberg, Jacqueline A. Gibbons, and Tiffany A. Traina



Table of Contents





- 4055** **NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer**
Cynthia X. Ma, Feng Gao, Jingqin Luo, Donald W. Northfelt, Matthew Goetz, Andres Forero, Jeremy Hoog, Michael Naughton, Foluso Ademuyiwa, Rama Suresh, Karen S. Anderson, Julie Margenthaler, Rebecca Aft, Timothy Hobday, Timothy Moynihan, William Gillanders, Amy Cyr, Timothy J. Eberlein, Tina Hieken, Helen Krontriras, Zhanfang Guo, Michelle V. Lee, Nicholas C. Spies, Zachary L. Skidmore, Obi L. Griffith, Malachi Griffith, Shana Thomas, Caroline Bumb, Kiran Vij, Cynthia Huang Bartlett, Maria Koehler, Hussam Al-Kateb, Souzan Sanati, and Matthew J. Ellis
- 4066** **Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline *BRCA1*- or *BRCA2*-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083**
George Somlo, Paul H. Frankel, Banu K. Arun, Cynthia X. Ma, Agustin A. Garcia, Tessa Cigler, Leah V. Cream, Harold A. Harvey, Joseph A. Sparano, Rita Nanda, Helen K. Chew, Timothy J. Moynihan, Linda T. Vahdat, Matthew P. Goetz, Jan H. Beumer, Arti Hurria, Joanne Mortimer, Richard Piekarz, Sharon Sand, Josef Herzog, Lily R. Van Tongeren, Katherine V. Ferry-Galow, Alice P. Chen, Christopher Ruel, Edward M. Newman, David R. Gandara, and Jeffrey N. Weitzel
- 4077** **Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes**
Chen Wang, Sebastian M. Armasu, Kimberly R. Kalli, Matthew J. Maurer, Ethan P. Heinzen, Gary L. Keeney, William A. Cliby, Ann L. Oberg, Scott H. Kaufmann, and Ellen L. Goode
- 4086** **Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization**
Stephanie Lheureux, Zhongwu Lai, Brian A. Dougherty, Sarah Runswick, Darren R. Hodgson, Kirsten M. Timms, Jerry S. Lanchbury, Stan Kaye, Charlie Gourley, David Bowtell, Elise C. Kohn, Claire Scott, Ursula Matulonis, Tony Panzarella, Katherine Karakasis, Julia V. Burnier, C. Blake Gilks, Mark J. O'Connor, Jane D. Robertson, Jonathan Ledermann, J. Carl Barrett, Tony W. Ho, and Amit M. Oza
- 4095** **A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline *BRCA1/2*-Mutated Ovarian Carcinoma or Other Solid Tumors**
 Rebecca Kristeleit, Geoffrey I. Shapiro, Howard A. Burris, Amit M. Oza, Patricia LoRusso, Manish R. Patel, Susan M. Domchek, Judith Balmaña, Yvette Drew, Lee-may Chen, Tamar Safra, Ana Montes, Heidi Giordano, Lara Maloney, Sandra Goble, Jeff Isaacson, Jim Xiao, Jen Borrow, Lindsey Rolfe, and Ronnie Shapira-Frommer
- 4107** **Successful Transfer of Umbilical Cord Blood CD34⁺ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients**
Harry Dolstra, Mieke W.H. Roeven, Jan Spanholtz, Basav N. Hangalapura, Marleen Tordoir, Frans Maas, Marij Leenders, Fenna Bohme, Nina Kok, Carel Trilsbeek, Jos Paardekooper, Anniek B. van der Waart, Peter E. Westerweel, Tjeerd J.F. Snijders, Jan Cornelissen, Gerard Bos, Hans F.M. Pruijt, Aniek O. de Graaf, Bert A. van der Reijden, Joop H. Jansen, Arnold van der Meer, Gerwin Huls, Jeannette Cany, Frank Preijers, Nicole M.A. Blijlevens, and Nicolaas M. Schaap
- 4119** **The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma**
Jacob D. Soumerai, Andrew D. Zelenetz, Craig H. Moskowitz, M. Lia Palomba, Paul A. Hamlin Jr, Ariela Noy, David J. Straus, Alison J. Moskowitz, Anas Younes, Matthew J. Matasar, Steven M. Horwitz, Carol S. Portlock, Jason A. Konner, Mrinal M. Gounder, David M. Hyman, Martin H. Voss, Matthew G. Fury, Devika Gajria, Richard D. Carvajal, Alan L. Ho, Jan H. Beumer, Brian Kiesel, Zhigang Zhang, Alice Chen, Richard F. Little, Christine Jarjies, Thu O. Dang, Fallon France, Nishant Mishra, and John F. Gerecitano
- 4127** **A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma**
 Myron S. Czuczman, Marek Trněný, Andrew Davies, Simon Rule, Kim M. Linton, Nina Wagner-Johnston, Randy D. Gascoyne, Graham W. Slack, Pierre Brousset, David A. Eberhard, Francisco J. Hernandez-Ilizaliturri, Gilles Salles, Thomas E. Witzig, Pier Luigi Zinzani, George W. Wright, Louis M. Staudt, Yandan Yang, P. Mickey Williams, Chih-Jian Lih, Jacqueline Russo, Anjan Thakurta, Patrick Hagner, Pierre Fustier, Dale Song, and Ian D. Lewis

Table of Contents

- 4138** A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma
Patrick M. Dillon, Gina R. Petroni, Bethany J. Horton, Christopher A. Moskaluk, Paula M. Fracasso, Michael G. Douvas, Nikole Varhegyi, Snjezana Zaja-Milatovic, and Christopher Y. Thomas
- 4146** Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
Christine M. Parseghian, Nila U. Parikh, Ji Yuan Wu, Zhi-Qin Jiang, Laura Henderson, Feng Tian, Brice Pastor, Marc Ychou, Kanwal Raghav, Arvind Dasari, David R. Fogelman, Anastasia D. Katsiampoura, David G. Menter, Robert A. Wolff, Cathy Eng, Michael J. Overman, Alain R. Thierry, Gary E. Gallick, and Scott Kopetz
- 4155**  Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act
Kenneth L. Kehl, Cheryl P. Fullmer, Siqing Fu, Goldy C. George, Kenneth R. Hess, Filip Janku, Daniel D. Karp, Shumei Kato, Cynthia K. Kizer, Razelle Kurzrock, Aung Naing, Shubham Pant, Sarina A. Piha-Paul, Vivek Subbiah, Apostolia M. Tsimberidou, and David S. Hong
- 4163** First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors
Mark N. Stein, Joseph R. Bertino, Howard L. Kaufman, Tina Mayer, Rebecca Moss, Ann Silk, Nancy Chan, Jyoti Malhotra, Lorna Rodriguez, Joseph Aisner, Robert D. Aiken, Bruce G. Haffty, Robert S. DiPaola, Tracie Saunders, Andrew Zloza, Sherri Damare, Yasmeen Beckett, Bangning Yu, Saltanat Najmi, Christian Gabel, Siobhan Dickerson, Ling Zheng, Wafik S. El-Deiry, Joshua E. Allen, Martin Stogniew, Wolfgang Oster, and Janice M. Mehnert
- 4181** Added Value of Serum Hormone Measurements in Risk Prediction Models for Breast Cancer for Women Not Using Exogenous Hormones: Results from the EPIC Cohort
Anika Hüsing, Renée T. Fortner, Tilman Kühn, Kim Overvad, Anne Tjønneland, Anja Olsen, Marie-Christine Boutron-Ruault, Gianluca Severi, Agnes Fournier, Heiner Boeing, Antonia Trichopoulou, Vassiliki Benetou, Philippos Orfanos, Giovanna Masala, Valeria Pala, Rosario Tumino, Francesca Fasanelli, Salvatore Panico, H. Bas Bueno de Mesquita, Petra H. Peeters, Carla H. van Gills, J. Ramón Quirós, Antonio Agudo, Maria-Jose Sánchez, Maria-Dolores Chirlaque, Aurelio Barricarte, Pilar Amiano, Kay-Tee Khaw, Ruth C. Travis, Laure Dossus, Kuanrong Li, Pietro Ferrari, Melissa A. Merritt, Ioanna Tzoulaki, Elio Riboli, and Rudolf Kaaks
- 4190** ⁶⁴Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer
Helen Lee, Anthony F. Shields, Barry A. Siegel, Kathy D. Miller, Ian Krop, Cynthia X. Ma, Patricia M. LoRusso, Pamela N. Munster, Karen Campbell, Daniel F. Gaddy, Shannon C. Leonard, Elena Geretti, Stephanie J. Blocker, Dmitri B. Kirpotin, Victor Moyo, Thomas J. Wickham, and Bart S. Hendriks
- 4203** IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2⁺ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831
Monica M. Reinholz, Beiyun Chen, Amylou C. Dueck, Kathleen Tenner, Karla Ballman, Darren Riehle, Robert B. Jenkins, Xochiquetzal J. Geiger, Ann E. McCullough, and Edith A. Perez
- 4212**  B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Leo Zhang, Krystle Nomie, Hui Zhang, Taylor Bell, Lan Pham, Sabah Kadri, Jeremy Segal, Shaoying Li, Shouhao Zhou, David Santos, Shawana Richard, Shruti Sharma, Wendy Chen, Onyekachukwu Oriabure, Yang Liu, Shengjian Huang, Hui Guo, Zhihong Chen, Wenjing Tao, Carrie Li, Jack Wang, Bingliang Fang, Jacqueline Wang, Lei Li, Maria Badillo, Makhdum Ahmed, Selvi Thirumurthi, Steven Y. Huang, Yiping Shao, Laura Lam, Qing Yi, Y. Lynn Wang, and Michael Wang

PERSONALIZED MEDICINE AND IMAGING


- 4170**  Identification of a Novel ITC $\alpha_v\beta_6$ -Binding Peptide Using Protein Separation and Phage Display
Annette Altmann, Max Sauter, Saskia Roesch, Walter Mier, Rolf Warta, Jürgen Debus, Gerhard Dyckhoff, Christel Herold-Mende, and Uwe Haberkorn

Table of Contents







- 4224**  **Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone**
M. Reza Abbasi, Fikret Rifatbegovic, Clemens Brunner, Georg Mann, Andrea Ziegler, Ulrike Pötschger, Roman Crazzolara, Marek Ussowicz, Martin Benesch, Georg Ebetsberger-Dachs, Godfrey C.F. Chan, Neil Jones, Ruth Ladenstein, Inge M. Ambros, and Peter F. Ambros
- 4233**  **Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI**
Rafal Panek, Liam Welsh, Lauren C.J. Baker, Maria A. Schmidt, Kee H. Wong, Angela M. Riddell, Dow-Mu Koh, Alex Dunlop, Dualta Mcquaid, James A. d'Arcy, Shreerang A. Bhide, Kevin J. Harrington, Christopher M. Nutting, Georgina Hopkinson, Cheryl Richardson, Carol Box, Suzanne A. Eccles, Martin O. Leach, Simon P. Robinson, and Kate L. Newbold
- 4242** **Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate**
Shumei Kato, Aaron Goodman, Vighnesh Walavalkar, Donald A. Barkauskas, Andrew Sharabi, and Razelle Kurzrock
- 4251** **Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer**
A.J. van der Wekken, R. Pelgrim, N. 't Hart, N. Werner, M.F. Mastik, L. Hendriks, E.H.F.M. van der Heijden, M. Looijen-Salamon, A.J. de Langen, J. Staal-van den Brekel, S. Riemersma, B.E. van den Borne, E.J.M. Speel, A-M.C. Dingemans, T.J.N. Hiltermann, A. van den Berg, W. Timens, E. Schuurig, and H.J.M. Groen
- 4259**  **Radiomics Features of Multiparametric MRI as Novel Prognostic Factors in Advanced Nasopharyngeal Carcinoma**
Bin Zhang, Jie Tian, Di Dong, Dongsheng Gu, Yuhao Dong, Lu Zhang, Zhouyang Lian, Jing Liu, Xiaoning Luo, Shufang Pei, Xiaokai Mo, Wenhui Huang, Fusheng Ouyang, Baoliang Guo, Long Liang, Wenbo Chen, Changhong Liang, and Shuixing Zhang
- 4280** **Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells**
Deepika Sharma Das, Abhishek Das, Arghya Ray, Yan Song, Mehmet Kemal Samur, Nikhil C. Munshi, Dharminder Chauhan, and Kenneth C. Anderson
- 4290**  **Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma**
Xiaoyan Feng, Li Zhang, Chirag Acharya, Gang An, Kenneth Wen, Lugui Qiu, Nikhil C. Munshi, Yu-Tzu Tai, and Kenneth C. Anderson
- 4301**  **Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IκB and Downregulation of Survivin**
Jayasree S. Nair, Elgilda Musi, and Gary K. Schwartz
- 4312** **Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients**
Carmine Carbone, Geny Piro, Francesca Simionato, Francesca Ligorio, Chiara Cremolini, Fotios Loupakis, Greta Ali, Daniele Rossini, Valeria Merz, Raffaella Santoro, Camilla Zecchetto, Marco Zanotto, Federica Di Nicolantonio, Alberto Bardelli, Gabriella Fontanini, Giampaolo Tortora, and Davide Melisi
- 4323** **HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2**
Ariella B. Hanker, Joan T. Garrett, Mónica Valeria Estrada, Preston D. Moore, Paula González Ericsson, James P. Koch, Emma Langley, Sharat Singh, Phillip S. Kim, Garrett M. Frampton, Eric Sanford, Philip Owens, Jennifer Becker, M. Reid Groseclose, Stephen Castellino, Heikki Joensuu, Jens Huober, Jan C. Brase, Samira Majjaj, Sylvain Brohée, David Venet, David Brown, José Baselga, Martine Piccart, Christos Sotiropoulos, and Carlos L. Arteaga
- 4335**  **Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models**
Mari I. Suominen, Katja M. Fagerlund, Jukka P. Rissanen, Yvonne M. Konkol, Jukka P. Morko, ZhiQi Peng, Esa J. Alhoniemi, Salla K. Laine, Eva Corey, Dominik Mumberg, Karl Ziegelbauer, Sanna-Maria Käkönen, Jussi M. Halleen, Robert L. Vessella, and Arne Scholz
- CANCER THERAPY: PRECLINICAL**
- 4270** **PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors**
Harriet M. Kluger, Christopher R. Zito, Gabriela Turcu, Marina K. Baine, Hongyi Zhang, Adebowale Adeniran, Mario Sznol, David L. Rimm, Yuval Kluger, Lieping Chen, Justine V. Cohen, and Lucia B. Jilaveanu

Table of Contents

4347 Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer

Yasmine Assadipour, Nikolaos Zacharakis, Jessica S. Crystal, Todd D. Prickett, Jared J. Gartner, Robert P.T. Somerville, Hui Xu, Mary A. Black, Li Jia, Harshini Chinnasamy, Isaac Kriley, Lily Lu, John R. Wunderlich, Zhili Zheng, Yong-Chen Lu, Paul F. Robbins, Steven A. Rosenberg, Stephanie L. Goff, and Steven A. Feldman

4354 The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma

Caitlin D. Lowery, Alle B. VanWye, Michele Dowless, Wayne Blosser, Beverly L. Falcon, Julie Stewart, Jennifer Stephens, Richard P. Beckmann, Aimee Bence Lin, and Louis F. Stancato

4364 Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity *In Vitro*

Sandra Rebouissou, Tiziana La Bella, Samia Rezik, Sandrine Imbeaud, Anna-Line Calatayud, Nataliya Rohr-Udilova, Yoann Martin, Gabrielle Couchy, Paulette Bioulac-Sage, Bettina Grasl-Kraupp, Leanne de Koning, Nathalie Ganne-Carrié, Jean-Charles Nault, Marianne Zioli, and Jessica Zucman-Rossi

4376 Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma

Haibo Sun, De-Chen Lin, Qi Cao, Brendan Pang, David D. Gae, Victor Kwan Min Lee, Huey Jin Lim, Ngan Doan, Jonathan W. Said, Sigal Gery, Marilyn Chow, Anand Mayakonda, Charles Forscher, Jeffrey W. Tyner, and H. Phillip Koeffler

4388 Lymphotoxin- β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer

Dennis Shin-Shian Hsu, Wei-Lun Hwang, Chiou-Hwa Yuh, Chen-Hsi Chu, Yang-Hui Ho, Pon-Bo Chen, Han-Syuan Lin, Hua-Kuo Lin, Shih-Pei Wu, Chih-Yi Lin, Wen-Hao Hsu, Hsin-Yi Lan, Hsiao-Jung Wang, Shyh-Kuan Tai, Mien-Chie Hung, and Muh-Hwa Yang

BIOLOGY OF HUMAN TUMORS

4402 Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases

Charlotte K.Y. Ng, Francois-Clement Bidard, Salvatore Piscuoglio, Felipe C. Geyer, Raymond S. Lim, Ino de Bruijn, Ronglai Shen, Fresia Pareja, Samuel H. Berman, Lu Wang, Jean-Yves Pierga, Anne Vincent-Salomon, Agnes Viale, Larry Norton, Brigitte Sigal, Britta Weigelt, Paul Cottu, and Jorge S. Reis-Filho

4416 Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma

Nicolas A. Giraldo, Etienne Becht, Yann Vano, Florent Petitprez, Laetitia Lacroix, Pierre Validire, Rafael Sanchez-Salas, Alexandre Ingels, Stephane Oudard, Audrey Moatti, Benedicte Buttard, Sarah Bourass, Claire Germain, Xavier Cathelineau, Wolf H. Fridman, and Catherine Sautès-Fridman

4429 Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers

Erik S. Knudsen, Paris Vail, Uthra Balaji, Hoai Ngo, Ihab W. Botros, Vladimir Makarov, Nadeem Riaz, Vinod Balachandran, Steven Leach, Debrah M. Thompson, Timothy A. Chan, and Agnieszka K. Witkiewicz

4441 Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project

Bo Hwa Sohn, Jun-Eul Hwang, Hee-Jin Jang, Hyun-Sung Lee, Sang Cheul Oh, Jae-Jun Shim, Keun-Wook Lee, Eui Hyun Kim, Sun Young Yim, Sang Ho Lee, Jae-Ho Cheong, Woojin Jeong, Jae Yong Cho, Joohee Kim, Jungsoo Chae, Jeeyun Lee, Won Ki Kang, Sung Kim, Sung Hoon Noh, Jaffer A. Ajani, and Ju-Seog Lee

4450 Jab1/Csn5–Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress

Fuling Zhou, Yunbao Pan, Yongchang Wei, Ronghua Zhang, Gaigai Bai, Qiuju Shen, Shan Meng, Xiao-Feng Le, Michael Andreeff, and Francois X. Claret

4462 PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma

Ombretta Melaiu, Marco Mina, Marco Chierici, Renata Boldrini, Giuseppe Jurman, Paolo Romania, Valerio D'Alicandro, Maria C. Benedetti, Aurora Castellano, Tao Liu, Cesare Furlanello, Franco Locatelli, and Doriana Fruci



Table of Contents

4473 Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters

Janelle B. Pakish, Qian Zhang, Zhongyuan Chen, Han Liang, Gary B. Chisholm, Ying Yuan, Samuel C. Mok, Russell R. Broaddus, Karen H. Lu, and Melinda S. Yates

4482 Vascular CXCR4 Expression Promotes Vessel Sprouting and Sensitivity to Sorafenib Treatment in Hepatocellular Carcinoma

Jing Xu, Jing Liang, Ya-Ming Meng, Jing Yan, Xing-Juan Yu, Chao-Qun Liu, Li Xu, Shi-Mei Zhuang, and Limin Zheng

4493 Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer

Sean P. Pitroda, Riyue Bao, Jorge Andrade, Ralph R. Weichselbaum, and Philip P. Connell

4501 Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3

Johanne I. Weberpals, Bryan Lo, Marc M. Duciaume, Johanna N. Spaans, Aisling A. Clancy, Jim Dimitroulakos, Glenwood D. Goss, and Harman S. Sekhon

4511 Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis



Qingyu Xu, Yan Li, Na Lv, Yu Jing, Yihan Xu, Yuyan Li, Wenjun Li, Zilong Yao, Xiaosu Chen, Sai Huang, Lili Wang, Yonghui Li, and Li Yu

RETRACTION

4523 Retraction: Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216




AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows a section of a primary tumor at diagnosis from a patient with metastatic colon cancer who failed a bevacizumab-containing regimen as first-line treatment. Immunohistochemical staining shows HOXB9 expression in tumor cells. For details, see the article by Carbone and colleagues on page 4312 of this issue.



Clinical Cancer Research

23 (15)

Clin Cancer Res 2017;23:3975-4523.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/23/15>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/23/15>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.